| Autor: |
Satoshi Saito, Kaori Shinmyozu, Daisuke Kawakami, Miho Yamauchi, Shuhei Ikeda, Yorito Hattori, Rintaro Yamamoto, Naoki Hayakawa, Masafumi Ihara |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2352-8737 |
| DOI: |
10.1002/trc2.12182 |
| Popis: |
Abstract Introduction Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites (n = 19, P = .005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores (P = .036) than patients with lower ratios (the ratio |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text